Fri, Jul 11, 2014, 10:51 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

hbomb57108 42 posts  |  Last Activity: Jul 9, 2014 8:47 PM Member since: Mar 26, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Trial sites activated for Renal and HCC

    by hbomb57108 Jul 8, 2014 9:08 PM
    hbomb57108 hbomb57108 Jul 9, 2014 8:47 PM Flag

    "72 plus months "

    72 plus weeks obviously. I also buy into Ernie's assertion that Cabo will have plenty of patients to treat even if/when Nivolumab were to enter market. Not everyone responded to Nivolumab.

  • Reply to

    Trial sites activated for Renal and HCC

    by hbomb57108 Jul 8, 2014 9:08 PM
    hbomb57108 hbomb57108 Jul 9, 2014 8:38 PM Flag

    "HCC should be a relatively uncontested indication for Cabo. I don't think the results were nearly so good for Tivantinib"

    Right, it will be interesting to see how this market shapes up. Even if Tivantinib were successful, Cabo has a decent financial opportunity on a global scale. I think Cabo early renal data was very strong in heavily pretreated renal cancer population. Maybe underappreciated, and I would like to see eventual OS data. I think Cabo data may be closer to Nivolumab data than you may think. Those bone responses and pain relief going out 72 plus months were pretty compelling. I noticed the recent Cabo patent on bone pain relief and bone involvement.---For lung,melanoma,prostate,thyroid, and renal.cancers.

  • Reply to

    Trial sites activated for Renal and HCC

    by hbomb57108 Jul 8, 2014 9:08 PM
    hbomb57108 hbomb57108 Jul 9, 2014 7:56 PM Flag

    "RCC(METEOR) 198 out of 211 sites actively recruiting"

    Yesterdays update now shows 201 of 211

  • Reply to

    When is the next big calalyst on this one?

    by smithts777 Jul 5, 2014 12:36 PM
    hbomb57108 hbomb57108 Jul 8, 2014 9:19 PM Flag

    " The only guidance is that Roche expects to file an NDA in 2014. They need the results in hand soon to make that deadline."

    Guidance from Roche hasn't changed since recent phase 1 update demonstrating close to 14 months pfs with Cobi/Zelboraf combination? What is the number of events required to trigger interim analysis?

  • hbomb57108 by hbomb57108 Jul 8, 2014 9:10 PM Flag

    RCC(METEOR) 198 out of 211 sites actively recruiting

    HCC(CELESTIAL) 89 out of 139 actively recruiting

  • per clinicaltr ialdotg ov

    RCC(METEOR) 198 out of 211 sites actively recruiting

    HCC(CELESTIAL) 89 out of 139 actively recruiting

    Full recruitment for METEOR is probably right around the corner. CELESTIAL will probably get a much greater focus soon.

  • hbomb57108 hbomb57108 Jul 8, 2014 9:29 AM Flag

    No problem. I've been looking in MAPK direction for awhile now.

    Here is a good paper

    " A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation"

  • hbomb57108 hbomb57108 Jul 8, 2014 8:08 AM Flag

    "I don't think the impact of cabozantinib treatment has been defined as yet in terms of MAPK activation, at least I don't recall seeing it the lit..."

    The EXAM trial responses in RAS population is the best we have thus far.

    "The results showed that patients with RAS mutations also experienced a significant benefit in PFS with cabozantinib, with patients in the experimental arm achieving a median PFS of 47 weeks compared with 8 weeks in the placebo arm (HR = 0.15; 95% CI, 0.02-1.10; P = .0317)."

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 29, 2014 11:46 PM Flag

    Here is background information to support Exelixis's 24 month OS estimation for EXAM. I can't get a read on how many of those 5 patients long term treated patients had metastatic disease upon study entry.

    Background: Metastatic medullary thyroid cancer (MTC) carries a median survival of about two years (Modigliani et al. 1998; Roman et al. 2006). Cabozantinib inhibits three primary pathways implicated in MTC pathogenesis and progression: MET, vascular endothelial growth factor receptor-2 (VEGFR2), and RET. A phase I study was initiated in September 2005 in patients (pts) with advanced solid tumors. Methods: 85 pts, including 37 with MTC were enrolled to evaluate safety, pharmacokinetics, and to determine maximum-tolerated dose (MTD). Once the MTD of 140 mg freebase (equivalent to 175 mg malate salt) was determined, 20 metastatic or locally advanced MTC pts were enrolled in an MTD expansion cohort. 10/37 MTC pts achieved a confirmed partial response (cPR) (Kurzock et al. 2011). We report here on long-term disease control (DC), defined as cPR or progression-free at ≥ 24 months (m), in the MTC cohort.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 29, 2014 11:26 PM Flag

    "98 of the original 219 cabo arm patients were still receiving treatment. That was 3 years ago. It is unlikely (but certainly possible) that any are still on treatment"

    5 of 11 responders in phase 1 MTC population that included a total of 37 patients remained on treatment for median of 4.5 yrs. At the time of ASCO 2013 phase 1 MTC abstract, you can see from quote below that 1 patient was on drug for 73 months(6 years and 1 month) and counting.

    "5 of these 11 pts remain on treatment for a median time of 55 m (53-73m)"

    Here is the rest

    Results: After a minimum follow-up period of 52 m, 11 of 37 pts (30%) experienced DC, and have remained progression-free for 24 m. Time from diagnosis and time since development of metastatic disease was similar in patients with (11) or without (26) long term DC. As of 04 Dec 2012, 5 of these 11 pts remain on treatment for a median time of 55 m (53-73m). A best response of cPR was associated with long-term benefit: 4/5 pts continuing on treatment achieved cPR, one achieved SD. The adverse event profile of cabozantinib was generally predictable and adverse events were managed with symptomatic treatment and dose modifications. The median final dose for pts with long-term DC was 60 mg (range 20-140), with a median number of dose reductions of 2 (range 0E4). Reasons for dose reductions in two or more pts experiencing long-term DC included diarrhea (7), palmar-plantar erythrodysaesthesia syndrome/rash (6), mucositis/stomatitis (3), anorexia (3), nausea (2), and vomiting (2).

  • Sam Waksal took over XL647 and the phase 3 trial in NSCLC has been terminated. LOL, only enrolled 8 patients.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 10:01 PM Flag

    "70 HR means there is a 30% risk of death in control arm vs placebo, but is not solely based on median."

    30% reduction in risk of death.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 9:40 PM Flag

    "I just wonder if - ultimately - final approval considerations for Cabo in mCRPC may require additional ADCOM guidance with Comet-2 trial results in hand.

    I don't think we will have to worry about an ADCOM. If COMET 1 is stat sig for OS, I believe that alone will be sufficient for approval. After all, COMET 1 has an OS primary endpoint. ADCOM's would be a bigger consideration under PFS primary endpoints. I believe Cabo's safety data thus far will not warrant ADCOM upon a stat sig OS signal in COMET 1..

    " I can't think of a precedent for such an approval scenario, can you?"

    Provenge needed a second trial for approval with guidance. I don't have enough experience following too many biotechs to give a good answer despite giving one example. I have a feeling Provenge may be an outlier on trial with OS primary endpoint though.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 9:16 PM Flag

    "In earlier posts, you (and Ernie, I think) had discussed cabazitaxel approval based upon an HR =0.7, and in looking at the Sanofi website, I see this is also expressed as a range of 0.59 - 0.83. I take this to mean that some of the P3 treatment group outliers were likely not statsig, yet the median was acceptably significant."

    The range of 0.59-0.83 represents lower and upper bound range of 95% confidence interval. It basically means that if you did this experiment 100 times, there is a 95% chance the HR will fall within .59-.83.----I think, I don't mind if someone wanted to correct me if I am mistaken.

    Median survival is only one point in time on KM curve. The HR takes into account the whole range events on KM curve. There can be a wide discrepancy between control arm and placebo at 70% of events to 50% of events(median) to 30% of events. .70 HR means there is a 30% risk of death in control arm vs placebo, but is not solely based on median. The range of differences between control and placebo can be very different at different points in time. In TROPIC trial for example, the placebo arm actually looked better than control at 2 months. The control arm (Jevtana) was performing worse than placebo for first 3 months. If you look at KM curve of TROPIC, you will notice that Jevtana had the greatest benefit over placebo at approx. 28 months of treatment (tail end of KM survival curve)

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 2:59 PM Flag

    "If that separation were uniform on all plots on KM curve, we would be closer to .7 HR at that interim"

    To add further-- My guess is that early parts of KM curve are tighter demonstrating less benefit than further out on KM curve. I think part of this has to due with Cabo toxicity and earlier deaths in that arm as a result. As we get more events, they will represent more of the patients that responded much better than earlier patient events. I suspect the KM curves on final analysis will look similar to Jevtana in CRPC. First few months with no separation and the further out on curve, the better the separation. Despite a more tolerable dose in COMET 1, I suspect the same will be said when we finally get to peek at COMET 1 final KM curves.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 2:43 PM Flag

    "If that separation were that large on all parts of plot, the HR would be larger.---I'm thinking"

    Not with it today. I meant if Cabo demonstrated 6 month advantage separation on other plots on KM curve, the HR would be much better. Lower HR not higher than .825. If that separation were uniform on all plots on KM curve, we would be closer to .7 HR at that interim.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 2:34 PM Flag

    "If this ratio holds to the required event, will the trial have displayed statsig OS?
    A 6 month comparative mOS survival advantage seems adequate to me...
    Am I looking at this correctly?"

    The most important number is HR, which was .825. I suspect the 6 month Cabo advantage over placebo for the median had one of the largest separations on KM curve plot compared to other plots on graph. If that separation were that large on all parts of plot, the HR would be larger.---I'm thinking

    I don't know what is the required HR for stat sig, but remember this is a very small study. The hurdle for stat sig on this study is very large in comparison to COMET 1 for example.

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 2:25 PM Flag

    "Do the Lan & DeMets rules somehow apply also to unplanned, unscheduled IA's? As I see it, the interim you refer to was an unplanned unblinding of events by the FDA at a previously unintended event cycle. Is there another set of rules that applies?"

    I don't think any alpha was spent on unplanned unblinding done by FDA on June 2012 cutoff. That said, I am not very knowledgable on Alpha spend subject. The FDA was referencing April 6, 2011 cutoff (I may have mistakenly referenced June 2011 rather than actual April 2011 cutoff) with this quote

    "An interim analysis of OS was expected to be performed at the 0.00006 level per a Lan-DeMets
    O’Brien-Fleming alpha spending function based on an expected 31% information level. The
    actual alpha level was based on the actual information fraction at the time of the analysis. If the
    result of the interim analysis for OS was not significant, the primary analysis of OS would be
    performed when the required number of deaths (217) had been observed. The primary analysis
    was expected to be conducted at the 0.04 significance level per the alpha spending function.

    The pre-specified interim analysis of OS was performed at the time of the primary analysis of
    PFS and included 217 (44%) deaths required for the final analysis of this endpoint. The criterion
    for stopping early due to rejection of the null hypothesis at the interim analysis [based upon a
    significance level (0.0009)] was not met. No difference between study arms in the estimate of
    overall survival was observed"

  • Reply to

    Overall survival in MTC

    by wilderguide Jun 28, 2014 1:19 PM
    hbomb57108 hbomb57108 Jun 28, 2014 1:59 PM Flag

    "Though I realize EXAM has enlisted an advanced patient group, the fact remains that MTC is a slow killer and I suspect many afflicted patients that receive advanced therapy beyond surgery and RT actually manage to outlive the disease. Patience is a requirement here..."

    In EXAM population that only included progressive disease, the OS was estimated at approx. 20 months if I recall. Final enrollment concluded on Feb of 2011. At June 2011 cutoff, 96 events occurred out of 330. At June 2012 cutoff, 66 more events occurred in 1 years time frame. Two years have passed needing only 55 more events. We are awfully close IMHO. I wouldn't be surprised if they are cleaning data as we speak.

    FWIW median OS on Cabo arm was 26 months and Placebo at 20 months at 162 events of the total 217 needed for final analysis.

  • Reply to

    EXAM trial

    by hbomb57108 Jun 28, 2014 2:24 AM
    hbomb57108 hbomb57108 Jun 28, 2014 1:14 PM Flag

    "Below is quote from safety review with EXAM "

    typo meant first interim after 96 OS events. The updated second (unplanned interim cutoff 6/15/2012) had 162 OS events broken down as follows

    Cabo N=219 Placebo N=111

    Cabo events=103(47%) Placebo events=59 (53%)

EXEL
3.325+0.075(+2.31%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
ACI Worldwide, Inc.
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
MGIC Investment Corp.
NYSEFri, Jul 11, 2014 4:01 PM EDT